1
|
Humar A, Asberg A, Kumar D, Hartmann A, Moussa G, Jardine A, Rollag H, Mouas H, Gahlemann CG, Pescovitz MD. An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes. Am J Transplant 2009; 9:374-81. [PMID: 19120074 DOI: 10.1111/j.1600-6143.2008.02501.x] [Citation(s) in RCA: 62] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The effect of herpesvirus co-infections (HHV-6, HHV-7) on cytomegalovirus (CMV) disease and its response to therapy is unknown. We prospectively analyzed herpesvirus co-infections in transplant recipients with CMV disease. All patients received 3 weeks of antiviral therapy. Samples were collected at baseline (day 0) and then day 3, 7, 14 and 21 poststart of therapy. Viral load testing for CMV, HHV-6 and HHV-7 was done using quantitative PCR assays in 302 patients of whom 256 had documented symptomatic CMV viremia. In this subset, day 0 HHV-6 co-infection was present in 23/253 (9.1%) and HHV-7 in 17/253 (6.7%). Including those positive at any time point raised the prevalence to 79/256 (30.9%) for HHV-6 and 75/256 (29.3%) for HHV-7. Viral co-infection did not influence the response of CMV disease to antiviral therapy. Baseline CMV viral loads, time to eradication and risk of recurrence were similar in patients with and without HHV-6 or HHV-7 co-infection. Ganciclovir and valganciclovir had no clear effect on HHV-6 and HHV-7 viremia. In conclusion, herpesvirus co-infections are common in patients with CMV disease but with standard antiviral therapy, no clear clinical effects are discernable. Routine monitoring for viral co-infection in patients with CMV disease is not indicated.
Collapse
Affiliation(s)
- A Humar
- Department of Medicine, University of Alberta, Edmonton, AB, Canada.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Hochhaus A, Hofheinz R, Heike M, Schlag R, Gahlemann CG, Kubicka S. Phase I study of gefitinib in combination with FOLFIRI as 2nd-/3rd-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3674] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. Hochhaus
- III. Med. Klin Mannheim, Univ Heidelberg, Mannheim, Germany; Med. Klin, Dortmund, Germany; Haematologisch-onkologische Praxis, Wuerzburg, Germany; AstraZeneca GmbH, Wedel, Germany; Med. Hochschule Hannover, Hannover, Germany
| | - R. Hofheinz
- III. Med. Klin Mannheim, Univ Heidelberg, Mannheim, Germany; Med. Klin, Dortmund, Germany; Haematologisch-onkologische Praxis, Wuerzburg, Germany; AstraZeneca GmbH, Wedel, Germany; Med. Hochschule Hannover, Hannover, Germany
| | - M. Heike
- III. Med. Klin Mannheim, Univ Heidelberg, Mannheim, Germany; Med. Klin, Dortmund, Germany; Haematologisch-onkologische Praxis, Wuerzburg, Germany; AstraZeneca GmbH, Wedel, Germany; Med. Hochschule Hannover, Hannover, Germany
| | - R. Schlag
- III. Med. Klin Mannheim, Univ Heidelberg, Mannheim, Germany; Med. Klin, Dortmund, Germany; Haematologisch-onkologische Praxis, Wuerzburg, Germany; AstraZeneca GmbH, Wedel, Germany; Med. Hochschule Hannover, Hannover, Germany
| | - C. G. Gahlemann
- III. Med. Klin Mannheim, Univ Heidelberg, Mannheim, Germany; Med. Klin, Dortmund, Germany; Haematologisch-onkologische Praxis, Wuerzburg, Germany; AstraZeneca GmbH, Wedel, Germany; Med. Hochschule Hannover, Hannover, Germany
| | - S. Kubicka
- III. Med. Klin Mannheim, Univ Heidelberg, Mannheim, Germany; Med. Klin, Dortmund, Germany; Haematologisch-onkologische Praxis, Wuerzburg, Germany; AstraZeneca GmbH, Wedel, Germany; Med. Hochschule Hannover, Hannover, Germany
| |
Collapse
|
3
|
Reck M, Gatzemeier U, Bucholz E, Gahlemann CG, Manegold C. An open-label, multi centre, phase II, non-comparative trial of ZD1839 monotherapy in chemotherapy-naive patients with stage IV or stage III non-operable non-small cell lung cancer (NSCLC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7098] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Reck
- Hosp Grosshansdorf, Grosshansdorf, Germany; Thoraxklinik Heidelberg Rohrbach, Heidelberg, Germany; AstraZeneca, Wedel, Germany
| | - U. Gatzemeier
- Hosp Grosshansdorf, Grosshansdorf, Germany; Thoraxklinik Heidelberg Rohrbach, Heidelberg, Germany; AstraZeneca, Wedel, Germany
| | - E. Bucholz
- Hosp Grosshansdorf, Grosshansdorf, Germany; Thoraxklinik Heidelberg Rohrbach, Heidelberg, Germany; AstraZeneca, Wedel, Germany
| | - C. G. Gahlemann
- Hosp Grosshansdorf, Grosshansdorf, Germany; Thoraxklinik Heidelberg Rohrbach, Heidelberg, Germany; AstraZeneca, Wedel, Germany
| | - C. Manegold
- Hosp Grosshansdorf, Grosshansdorf, Germany; Thoraxklinik Heidelberg Rohrbach, Heidelberg, Germany; AstraZeneca, Wedel, Germany
| |
Collapse
|
4
|
Arnold D, Constantin C, Seufferlein T, Gahlemann CG, Schmoll HJ, Kretzschmar A. Phase I study of gefitinib in combination with capecitabine and irinotecan for 2nd- and/or 3rd-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3691] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- D. Arnold
- Martin Luther Univ, Halle, Germany; Klin Lippe, Lemgo, Germany; Univ Hosp, Ulm, Germany; AstraZeneca Germany, Wedel, Germany; Charité Campus Berlin Buch, Berlin, Germany
| | - C. Constantin
- Martin Luther Univ, Halle, Germany; Klin Lippe, Lemgo, Germany; Univ Hosp, Ulm, Germany; AstraZeneca Germany, Wedel, Germany; Charité Campus Berlin Buch, Berlin, Germany
| | - T. Seufferlein
- Martin Luther Univ, Halle, Germany; Klin Lippe, Lemgo, Germany; Univ Hosp, Ulm, Germany; AstraZeneca Germany, Wedel, Germany; Charité Campus Berlin Buch, Berlin, Germany
| | - C. G. Gahlemann
- Martin Luther Univ, Halle, Germany; Klin Lippe, Lemgo, Germany; Univ Hosp, Ulm, Germany; AstraZeneca Germany, Wedel, Germany; Charité Campus Berlin Buch, Berlin, Germany
| | - H.-J. Schmoll
- Martin Luther Univ, Halle, Germany; Klin Lippe, Lemgo, Germany; Univ Hosp, Ulm, Germany; AstraZeneca Germany, Wedel, Germany; Charité Campus Berlin Buch, Berlin, Germany
| | - A. Kretzschmar
- Martin Luther Univ, Halle, Germany; Klin Lippe, Lemgo, Germany; Univ Hosp, Ulm, Germany; AstraZeneca Germany, Wedel, Germany; Charité Campus Berlin Buch, Berlin, Germany
| |
Collapse
|
5
|
Hartmann JT, Kroening H, Bokemeyer C, Holtmann M, Schmoll HJ, Kanz L, Gahlemann CG, Hoehler T. Phase I study of gefitinib in combination with oxaliplatin and weekly 5-FU/FA (FUFOX) for second-/third-line treatment in patients (pts) with metastatic colorectal cancer (CRC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3154] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. T. Hartmann
- Tuebingen Univ, Tuebingen, Germany; Onkological Practice, Magdeburg, Germany; Univ Medcl Ctr, Mainz, Germany; Martin-Luther-University Halle, Halle, Germany; AstraZeneca GmbH, Wedel, Germany
| | - H. Kroening
- Tuebingen Univ, Tuebingen, Germany; Onkological Practice, Magdeburg, Germany; Univ Medcl Ctr, Mainz, Germany; Martin-Luther-University Halle, Halle, Germany; AstraZeneca GmbH, Wedel, Germany
| | - C. Bokemeyer
- Tuebingen Univ, Tuebingen, Germany; Onkological Practice, Magdeburg, Germany; Univ Medcl Ctr, Mainz, Germany; Martin-Luther-University Halle, Halle, Germany; AstraZeneca GmbH, Wedel, Germany
| | - M. Holtmann
- Tuebingen Univ, Tuebingen, Germany; Onkological Practice, Magdeburg, Germany; Univ Medcl Ctr, Mainz, Germany; Martin-Luther-University Halle, Halle, Germany; AstraZeneca GmbH, Wedel, Germany
| | - H.-J. Schmoll
- Tuebingen Univ, Tuebingen, Germany; Onkological Practice, Magdeburg, Germany; Univ Medcl Ctr, Mainz, Germany; Martin-Luther-University Halle, Halle, Germany; AstraZeneca GmbH, Wedel, Germany
| | - L. Kanz
- Tuebingen Univ, Tuebingen, Germany; Onkological Practice, Magdeburg, Germany; Univ Medcl Ctr, Mainz, Germany; Martin-Luther-University Halle, Halle, Germany; AstraZeneca GmbH, Wedel, Germany
| | - C. G. Gahlemann
- Tuebingen Univ, Tuebingen, Germany; Onkological Practice, Magdeburg, Germany; Univ Medcl Ctr, Mainz, Germany; Martin-Luther-University Halle, Halle, Germany; AstraZeneca GmbH, Wedel, Germany
| | - T. Hoehler
- Tuebingen Univ, Tuebingen, Germany; Onkological Practice, Magdeburg, Germany; Univ Medcl Ctr, Mainz, Germany; Martin-Luther-University Halle, Halle, Germany; AstraZeneca GmbH, Wedel, Germany
| |
Collapse
|
6
|
Fischer L, Sterneck M, Gahlemann CG, Malago M, Rogiers X, Broelsch CE. A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients. Transplant Proc 2000; 32:2125-7. [PMID: 11120098 DOI: 10.1016/s0041-1345(00)01599-2] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- L Fischer
- Department of Hepatobiliary Surgery, University Hospital Hamburg Eppendorf, Hamburg, Germany
| | | | | | | | | | | |
Collapse
|